Opthea treats first patient in Phase 3 nAMD trial
The first patient in the Phase 3 clinical trial of a Melbourne-based drug company’s novel therapy for neovascular age-related macular ...
Tag: ASX
Australian optometry group acquired in $43 million deal
Australian optometry group The Optical Company (TOC) says it now has a clear mandate to expand its 41-store portfolio after ...
Aussie firm reveals next-gen MIGS device in pipeline
Adelaide ophthalmic device manufacturer Nova Eye Medical is developing a next generation iTrack glaucoma surgical system to reduce operating times. ...
Opthea becomes ASX top 300 company
Melbourne biopharmaceutical company Opthea has announced its inclusion on the ASX 300, just days after its lead drug candidate met ...
ACCC concludes investigation, clears Ellex-Lumibird deal
The Australian competition watchdog has cleared Ellex Medical Lasers’s $100 million sale of its laser and ultrasound business to Lumibird, ...